

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On July 3, 2002

DELTAGEN, INC.

By:

Don Mixon

Don Mixon

PATENT
Attorney Docket No.: R-605

TECH CENTER 1600/2900

JUL 15 2002

RECEIVED

7-15-02
P.2



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KEITH D. ALLEN, et al.

Application No.: 10/015,948

Filed: December 11, 2001

For: Transgenic Mice Containing
Andrenocorticotropin Hormone Receptor
Gene Disruptions

Examiner: Unassigned

Art Unit: 1642

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-1271. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Magriette A. Lapiz, Reg. No. 44,224

DELTAGEN, INC.
740 Bay Road
Redwood City, CA 94063
Tel: 650-569-5100
Fax: 650-569-5280

MAL/dxm

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/015,948
Filing Date	12/11/01
First Named Inventor	Keith D. Allen, et al.
Art Unit	1642
Examiner Name	Unassigned
Attorney Docket Number	R-605

JUL 09 2002

PCT CENTER 1600/2900

JUL 15 2002

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	MITSUMASA KUBO, et al. "Cloning of a mouse adrenocorticotropin receptor-encoding gene" <i>Gene</i> , Vol. 153 (1995), pp. 279-280	
	2	MARIE-CHRISTINE LEBRETHON, et al. "Regulation of Corticotropin Receptor Number and Messenger RNA in Cultured Human Adrenocortical Cells by Corticotropin and Angiotensin II" <i>J. Clin. Invest.</i> , Vol. 93, 04/94, pp. 1828-1833	
	3	KATHLEEN G. MOUNTJOY, et al. "The Cloning of a Family of Genes That Encode the Melanocortin Receptors" <i>Science</i> , Vol. 257, 08/28/92, pp. 1248-1251	
	4	DANIELLE NAVILLE, et al. "Genomic Structure and Promoter Characterization of the Human ACTH Receptor Gene" <i>Biochemical and Biophysical Research Communications</i> , Vol. 230, (1997), pp. 7-12	
	5	J. RAMACHANDRAN, "Corticotropin Receptors, Cyclic AMP and Steroidogenesis" <i>Endocrine Research</i> , Vol. 10(3&4), (1985), pp. 247-363	
	6	BERNARD P. SCHIMMER, "Cyclic Nucleotides in Hormonal Regulation of Adrenocortical Function" <i>Advances in Cyclic Nucleotide Research</i> , Vol. 13, (1980), pp. 181-214	
	7	ANGELA WEBER, et al., "Adrenocorticotropin Receptor Gene Mutations in Familial Glucocorticoid Deficiency: Relationships with Clinical Features in Four Families" <i>Journal of Clinical Endocrinology and Metabolism</i> , Vol. 80(1) (1995), pp. 65-71	

Examiner Signature	Date Considered
--------------------	-----------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unsaved Document